Israel’s Teva to buy Allergan Generics for $40.5bn
Israel’s Teva Pharmaceutical Industries entered an agreement with Allergan to acquire its generic drug unit Allergan Generics for $40.5bn.
Under the deal, Teva will pay $33.75bn in cash and provide $6.75bn worth of shares to Allergan, representing an estimated 10% ownership stake in Teva.
Go deeper with GlobalData
The acquired business is expected to transform Teva’s global generics space through expanding its generics pipeline, R&D capabilities, operational network, supply chain, global commercial deployment and infrastructure.
UK 15-year-old develops new test for Alzheimer’s disease
Teenager Krtin Nithiyanandam from Surrey, UK, developed a new test with the potential for early detection of Alzheimer’s disease.
Alzheimer’s is a chronic neurodegenerative disease and its early symptom is difficulty in remembering recent events (short-term memory loss).
Krtin’s new test was presented to the Google Science Fair Prize to help diagnose Alzheimer’s ten years before the first symptoms appear, reported The Telegraph.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataGarlic treats antimicrobial resistant urinary tract infections, says new study
Researchers from Birla Institute of Technology and Sciences in India revealed that garlic (allium sativum) can be used to combat antimicrobial resistant urinary tract infections (UTI).
Approximately 150 million people are diagnosed with UTIs per year worldwide and is claimed to be the second most common infectious disease found in community practice.
In the recent study published in the Pertanika Journal of Tropical Agricultural Science, garlic extract was found to be effective against multi-drug resistant strains of pathogenic bacteria associated with UTIs.
Blocking of DNA-PKcs prevents spread of tumour cells, say researchers
Researchers at Thomas Jefferson University discovered a new way to target a ‘lynchpin’ molecule to help prevent the spread of cancer.
According to the new study published in the journal Cancer Cell, experiments on laboratory mice with the human form of prostate cancer demonstrated that by targeting the same DNA repair kinase molecule DNA-PKcs, it is possible to prevent metastatic spread in human patients.
Metastasis is the spread of a cancer or disease from one organ or part to another not directly connected with it.
UK researchers repair damaged liver using stem cells
Researchers from the UK Medical Research Council (MRC) Centre for Regenerative Medicine at the University of Edinburgh successfully repaired damaged liver in a mouse through transplanting stem cells.
The mouse was suffering from liver failure. Scientists observed that areas of the liver have been grown from these cells over several months, enhancing the structure and function of their livers.
MRC science programmes director Dr Rob Buckle said: “This research has the potential to revolutionise patient care by finding ways of co-opting the body’s own resources to repair or replace damaged or diseased tissue.”
Immunovaccine and PharmAthene to develop new anthrax vaccine
Immunovaccine and PharmAthene signed an exclusive worldwide license agreement to develop and commercialise recombinant protective antigen anthrax vaccine (rPA) candidate.
Through using Immunovaccine’s proprietary DepoVax vaccine platform, the companies will develop an adjuvanted non-alum based rPA vaccine.
Under the deal, PharmAthene will secure exclusive worldwide rights from Immunovaccine to use DepoVax to develop and commercialise novel single dose anthrax vaccine.
CHMP recommends GSK’s Mosquirix vaccine to prevent malaria in young children
GlaxoSmithKline received a positive scientific opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for its malaria candidate vaccine, Mosquirix (RTS,S), to prevent the disease in children aged six weeks to 17 months.
The positive opinion will allow the World Health Organisation to formulate a policy recommendation on the use of the vaccine in national immunisation programmes once approved by national regulatory authorities.
Developed in collaboration with the PATH Malaria Vaccine Initiative, Mosquirix has been designed to prevent malaria caused by the Plasmodium falciparum parasite that is mostly predominant in sub-Saharan Africa.
Celgene to buy Receptos for $7.2bn
US-based Celgene signed an agreement to acquire biopharmaceutical firm Receptos for $7.2bn, allowing it to expand its inflammation and immunology (I&I) portfolio.
As part of the deal, Celgene will pay $232 per share in cash for Receptos, which is involved in developing therapeutic candidates to treat immune and metabolic diseases.
Celgene chairman Bob Hugin said: “The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas.”
